Document is current
Any future updates will be listed below
-
Authors
Holtjer, Judith C.S. https://orcid.org/0009-0008-2535-5357
Houweling, Laura
Downward, George S.
Bloemsma, Lizan D.
der Zee, Anke-Hilse Maitland-Van
Hoek, Gerard
-
Funding
Funding for this research was provided by:
Health~Holland (LSHM20104; LSHM20068)
- License Information
-
More Information
Article History
Received: 25 April 2025
Accepted: 9 September 2025
First Online: 20 September 2025
Declarations
:
: Statement.
: This study was approved by the ethical board of the Amsterdam University Medical Center (UMC), reference number NL74701.018.20.
: Written informed consent to participate in the P4O2 study was obtained for all participants.
: Written informed consent to publish the results of the P4O2 study was obtained for all participants.
: AHM reports financial support was provided by Health Holland. AHM reports financial support was provided by GSK. AHM reports financial support was provided by Boehringer Ingelheim. AHM reports financial support was providedby Sanofi. AHM reports financial support was provided by Astra Zeneca. AHM reports financial support was provided by Vertex. AHM reports a relationship with Boehringer Ingelheim that includes: consulting or advisory. AHM reports a relationship with Astra Zeneca that includes: consulting or advisory. AHM reports a relationship with GSK that includes: speaking and lecture fees. JCSH, LH, GSD, LDB, and RCHV are part of the Precision Medicine for more Oxygen (P4O2) consortium- a private public partnership. Partners in the P4O2 consortium are the Amsterdam UMC, Leiden University Medical Center, Maastricht UMC+, Maastricht University, UMC Groningen, UMC Utrecht, Utrecht University, TNO, Aparito, Boehringer Ingelheim, Breathomix, Clear, Danone Nutricia Research, Fluidda, MonitAir, Ncardia, Ortec Logiqcare,Philips, Proefdiervrij, Quantib-U, RespiQ, Roche, Smartfish, SODAQ, Thirona,TopMD, Lung Alliance Netherlands (LAN) and the Lung FoundationNetherlands (Longfonds). GH has no competing interest.
